-
Mashup Score: 39Activation of gp130 signaling in T cells drives TH17-mediated multi-organ autoimmunity - 24 day(s) ago
Genetic activation of a cytokine receptor in T cells in mice models a STAT3-driven autoimmune syndrome.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 38Activation of gp130 signaling in T cells drives TH17-mediated multi-organ autoimmunity - 29 day(s) ago
Genetic activation of a cytokine receptor in T cells in mice models a STAT3-driven autoimmune syndrome.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 53PD-1 inhibits T cell actin remodeling at the immunological synapse independently of its signaling motifs - 4 month(s) ago
A mechanism by which the inhibitory receptor PD-1 suppresses T cell activation is revealed.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 54PD-1 inhibits T cell actin remodeling at the immunological synapse independently of its signaling motifs - 4 month(s) ago
A mechanism by which the inhibitory receptor PD-1 suppresses T cell activation is revealed.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis | Lupus Science and Medicine Podcast - 5 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure. Read the related article – http://dx.doi.org/10.1136/lupus-2023-000932
Source: lupusbmj.podbean.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis | Lupus Science and Medicine Podcast - 6 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure. Read the related article – http://dx.doi.org/10.1136/lupus-2023-000932
Source: lupusbmj.podbean.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1Rheumatology & Autoimmunity - 6 month(s) ago
Click on the title to browse this journal
Source: onlinelibrary.wiley.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis | Lupus Science and Medicine Podcast - 6 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure. Read the related article – http://dx.doi.org/10.1136/lupus-2023-000932
Source: lupusbmj.podbean.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Objective The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) system is a novel and simple SLE disease activity instrument, consisting of a tandem clinician-reported (ClinRO) and patient-reported (PRO) outcome measure. The aim of this study was to compare the LFA-REAL system with other SLE activity measures in the phase III trial of ustekinumab in patients with active SLE. Methods This was a prespecified analysis of data from a randomised, double-blind, placebo-controlled, parallel-group trial conducted at 140 sites in 20 countries. Correlations were evaluated between the LFA-REAL ClinRO and PRO with a panel of clinician-reported and patient-reported disease activity measures commonly used in SLE clinical trials at baseline, week 24 and week 52. All p values are reported as nominal. Results Trial participants included 516 patients with SLE with a mean (SD) age of 43.5 (8.9), of whom 482 (93.4%) were female. The LFA-REAL ClinRO correlated with Physician Glob
Source: lupus.bmj.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1Belimumab shows promise in neuropsychiatric lupus: Another challenge to find the offender - 7 month(s) ago
Belimumab shows promise in neuropsychiatric lupus. Posterior reversible encephalopathy syndrome (PRES) frequently occurs during active systemic lupus erythematosus (SLE). The nephrotic state is a uni…
Source: onlinelibrary.wiley.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
Engineering a new mouse model of #autoimmunity, researchers have made strides in understanding the basis of a mysterious and rare autoimmune disorder named STAT3-GOF syndrome and identify several sex-specific differences in the disease. @SciSignal https://t.co/FUA6U5Yrxs https://t.co/jJjZ5s19IS